Xue et al. (2011) revealed that serum RCOR3 level can reflect liver injury degree and it is a biomarker of intrahepatic cholangiocarcinoma (Lv et al., 2017). In addition, RCOR3 shows lower expression in colorectal cancer patients, with hypermethylation on promoters (Liu et al., 2019). However, the underlying therapeutic and prognostic mechanisms of RCORs in cancer remain unclear. This evidence concerns the gene RCOR3 and intrahepatic cholangiocarcinoma.